---
title: Dabrafenib plus Trametinib in Pediatric Glioma with <em>BRAF</em> V600 Mutations
date: '2023-09-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37733309/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230921191728&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Among pediatric patients with low-grade glioma with BRAF
  V600 mutations, dabrafenib plus trametinib resulted in significantly more responses,
  longer progression-free survival, and a better safety profile than standard chemotherapy
  as first-line therapy. (Funded by Novartis; ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Among pediatric patients with low-grade glioma with BRAF V600 mutations, dabrafenib plus trametinib resulted in significantly more responses, longer progression-free survival, and a better safety profile than standard chemotherapy as first-line therapy. (Funded by Novartis; ClinicalTrials.gov number, ...